In that sense, androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists, antiandrogens, or surgical castration is initially recommended [4] and typically leads to a 90–95% decrease in circulating androgen levels and prevents tumor cell survival. This evidence concerns the gene GNRH1 and neoplasm.